Novabay Pharmaceuticals (NYSEAMERICAN: NBY)

NovaBay Pharmaceuticals (NYSEAMERICAN: NBY)

Official NovaBay Pharmaceuticals Logo

NovaBay Pharmaceuticals, Inc. (NYSEAMERICAN: NBY) is a commercial stage biopharmaceutical company headquartered in Emergyville, California. Founded in the year 2000, the company has three products currently on the market. These include:

Avenova – A product designed for daily eyelash and eyelid hygiene, cleaning bacteria that are known to contribute to 85% of the dry eye market.
NeutroPhase – A product designed for skin and wound care.
CelleRx – A clensing solution that cleans, calms and soothes after cosmetic procedures.

Visit the NovaBay Pharmaceuticals investor relations website here.

Recent Novabay Pharmaceuticals (NYSEAMERICAN: NBY) Reports From Alpha Stock News

NovaBay Pharmaceuticals (NBY) Stock Rockets On Sales

Joshua Rodriguez - July 29, 2019

NovaBay Pharmaceuticals (NBY) Stock Falls But Not For Long

June 12, 2019

NovaBay Pharmaceuticals (NBY) Stock Continues Skyward

June 11, 2019

Recent NovaBay Pharmaceuticals (NYSEAMERICAN: NBY) Press Releases

NovaBay Pharmaceuticals Announces Pricing of $2.7 Million Private Placement of Preferred Stock and Accompanying Warrants to Purchase Common Stock August 9, 2019
The closing of the sale of the securities is expected to take place on or about August 13, 2019, subject to the satisfaction of customary closing conditions. The preferred stock, the common stock convertible from the preferred stock, the accompanying warrants and the common stock issuable upon exercise of the warrants will not be registered […]
NovaBay Pharmaceuticals Announces Pricing of $4.2 Million Registered Direct Offering August 9, 2019
NovaBay® Pharmaceuticals, Inc. (NYSE American: NBY), a biopharmaceutical company focusing on commercializing Avenova for the domestic eye care market, today announced that it has entered into a securities purchase agreement with certain institutional investors providing for the purchase and sale of 4,198,566 shares of common stock at a price of $1.00 per share in a […]
NovaBay Pharmaceuticals Reports 2019 Second Quarter Financial Results August 7, 2019
Avenova® sales increase 9% and operating expenses decline 47% over the 2019 first quarter
NovaBay Pharmaceuticals Reports 2019 Second Quarter Net Sales of $1.8 Million July 29, 2019
NovaBay® Pharmaceuticals, Inc. (NYSE American: NBY), a biopharmaceutical company focusing on commercializing Avenova® for the domestic eye care market, reports net sales of $1.8 million for the three months ended June 30, 2019. Avenova sales for the second quarter of 2019 were $1.6 million, a 9% increase from the first quarter of 2019. “The increase […]
NovaBay Pharmaceuticals Issues Letter to Stockholders July 15, 2019
The second quarter of 2019 was transformative for NovaBay. NovaBay has made considerable advancements toward our goals of increasing Avenova accessibility and enhancing the patient experience, while maintaining product affordability in an evolving reimbursement environment. To achieve these goals, we have improved the efficiency of both our prescription sales and our buy-and-build channels, and launched […]